Cingulate Inc. Comprehensive Income
Cingulate Inc. (CING) reported Comprehensive Income of -$5.98 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2023-11-13
- Cingulate Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-09-30 was -$5.98M.
- Cingulate Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-06-30 was -$6.62M.
- Cingulate Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-03-31 was -$4.00M.
- Cingulate Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2022-09-30 was -$4.02M.
- Cingulate Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$20.71M.
- Cingulate Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$7.18M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$5.98M 10-Q · filed 2023-11-13 | -$12.60M derived: sum of 2 quarters · filed 2023-11-13 | -$16.60M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$6.62M 10-Q · filed 2023-08-14 | -$10.62M 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | -$4.00M 10-Q · filed 2023-05-10 | |||
| 2022-09-30 | -$4.02M 10-Q · filed 2023-11-13 | -$8.06M derived: sum of 2 quarters · filed 2023-11-13 | -$13.07M 10-Q · filed 2023-11-13 | -$15.73M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$4.04M 10-Q · filed 2023-08-14 | -$9.05M 10-Q · filed 2023-08-14 | -$11.70M derived: sum of 3 quarters · filed 2023-08-14 | -$26.99M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$5.01M 10-Q · filed 2023-05-10 | -$7.66M derived: sum of 2 quarters · filed 2023-05-10 | -$22.95M derived: sum of 3 quarters · filed 2023-05-10 | -$24.38M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$17.94M derived: sum of 2 quarters · filed 2022-11-14 | -$19.38M derived: sum of 3 quarters · filed 2022-11-14 | -$20.71M 10-K · filed 2022-03-28 |
| 2021-09-30 | -$15.29M 10-Q · filed 2022-11-14 | -$16.72M derived: sum of 2 quarters · filed 2022-11-14 | -$18.06M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$1.43M 10-Q · filed 2022-08-11 | -$2.77M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$1.33M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$7.18M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |